Fructose-1, 6-bisphosphatase inhibitors for reducing excessive endogenous glucose production in type 2 diabetes

Handbook of Experimental Pharmacology

Volumn 203, Issue , 2011, Pages 279-301

  Van Poelje, Paul D ^a   Potter, Scott C ^b   Erion, Mark D ^c  

^a PFIZER INC   (United States)

^b Lilly AME   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

AMP mimetic; Antihyperglycemic agent; Endogenous glucose production; Fructose 1,6 bisphosphatase; Gluconeogenesis; Type 2 diabetes

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE PHOSPHATE; ADENOSINE PHOSPHATE; ANTIDIABETIC AGENT; FRUCTOSE 1,6 BISPHOSPHATASE INHIBITOR; FRUCTOSE BISPHOSPHATASE; GLIBENCLAMIDE; GLUCOSE; INSULIN DERIVATIVE; INSULIN SENSITIZING AGENT; LACTIC ACID; LIPID; MANAGLINAT DIALANETIL; MB 05032; MB 07803; METFORMIN; PIOGLITAZONE; PLACEBO; UNCLASSIFIED DRUG; ALANINE; DRUG DERIVATIVE; ENZYME INHIBITOR; N,N' ((5 (2 AMINO 5 (2 METHYLPROPYL) 4 THIAZOLYL) 2 FURANYL)PHOSPHINYLIDENE)BIS(ALANINE) DIETHYL ESTER; N,N'-((5-(2-AMINO-5-(2-METHYLPROPYL)-4-THIAZOLYL)-2-FURANYL)PHOSPHINYLIDENE)BIS(ALANINE) DIETHYL ESTER; ORGANOPHOSPHORUS COMPOUND; PHOSPHONIC ACID DERIVATIVE;

DIET RESTRICTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME STRUCTURE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEFICIENCY; INSULIN RESISTANCE; LACTIC ACIDOSIS; LACTICEMIA; METABOLIC DISORDER; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; ANIMAL; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; SIGNAL TRANSDUCTION;

ALANINE; ANIMALS; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; FRUCTOSE-BISPHOSPHATASE; GLUCONEOGENESIS; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; SIGNAL TRANSDUCTION;

EID: 79955590704     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-17214-4_12     Document Type: Review

References (65)

1. Andrikopoulos S, Rosella G, Kaczmarczyk SJ, Zajac JD, Proietto J (1996) Impaired regulation of hepatic fructose-1, 6-biphosphatase in the New Zealand Obese mouse: an acquired defect. Metabolism 45(5):622-626 (Pubitemid 26146116)
2. Boden G, Chen X, Capulong E, Mozzoli M (2001) Effects of free fatty acids on gluconeogenesis and autoregulation of glucose production in type 2 diabetes. Diabetes 50:810-816 (Pubitemid 32242638)
3. Bruce SR, Walker J, Feins K, Tao B, Triscari J (2006) Initial safety, tolerability and glucose lowering of CS-917, a novel fructose 1, 6-bisphosphatase (FBPase) inhibitor, in subjects with type 2 diabetes. Diabetologia 49(Suppl 1):0037
4. Burgess SC, Hausler N, Merritt M, Jeffrey FM, Storey C, Milde A, Koshy S, Lindner J, Magnuson MA, Malloy CR, Sherry AD (2004) Impaired tricarboxylic acid cycle activity in mouse livers lacking cytosolic phosphoenolpyruvate carboxykinase. J Biol Chem 279:48941-48949 (Pubitemid 39625775)
5. Cherrington AD (1999) Banting Lecture: Control of glucose uptake and release by the liver in vivo. Diabetes 48:1198-1214
6. Choe JY, Nelson SW, Arienti KL, Axe FU, Collins TL, Jones TK, Kimmich RD, Newman MJ, Norvell K, Ripka WC, Romano SJ, Short KM, Slee DH, Fromm HJ, Honzatko RB (2003) Inhibition of fructose-1, 6-bisphosphatase by a new class of allosteric effectors. J Biol Chem 278:51176-51183 (Pubitemid 38020354)
7. Cryer DR, Nicholas SP, Henry DH, Mills DJ, Stadel BV (2005) Comparative outcomes study of metformin intervention versus conventional approach. Diab Care 28:539-543 (Pubitemid 40315310)
8. Dang Q, Kasibhatla SR, Reddy KR, Jiang T, Reddy MR, Potter SC, Fujitaki JM, van Poelje PD, Huang J, Lipscomb WN (2007) Erion MD (2007) Discovery of potent and specific fructose-1, 6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes. J Am Chem Soc 129(50):15491-15502
9. Dang Q, Kasibhatla SR, Jiang T, Fan K, Liu Y, Taplin F, Schulz W, Cashion DK, Reddy KR, van Poelje PD, Fujitaki JM, Potter SC, Erion MD (2008a) Discovery of phosphonic diamide prodrugs and their use for the oral delivery of a series of fructose 1, 6-bisphosphatase inhibitors. J Med Chem 51(14):4331-4339 (Pubitemid 352032458)
10. Dang Q, van Poelje PD, Lemus RH, Tian F, Potter SC, Fujitaki JM, Linemeyer D1, Erion ME (2008b) Discovery of a second generation FBPase inhibitor, MB07803, with reduced metabolism and improved oral bioavailability. 235th ACS Meeting, Medi-21
11. De Lombaert S, Erion MD, Tan J, Blanchard L, el-Chehabi L, Ghai RD, Sakane Y, Berry C, Trapani AJ (1994) N-Phosphonomethyl dipeptides and their phosphonate prodrugs, a new generation of neutral endopeptidase (NEP, EC 3.4.24.11) inhibitors. J Med Chem 37 (4):498-511
12. Dzugaj A, Kochman M (1980) Purification of human liver fructose-1, 6-bisphosphatase. Biochim Biophys Acta 614(2):407-412 (Pubitemid 11168406)
13. El-Maghrabi MR, Gidh-Jain M, Austin LR, Pilkis SJ (1993) Isolation of a human liver fructose 1, 6-bisphosphatase cDNA and expression of the protein in Escherichia coli. J Biol Chem 268:9466-9472 (Pubitemid 23145998)
14. El-Maghrabi MR, Lange AJ, Kummel L, Pilkis SJ (1991) The rat fructose-1, 6-bisphosphatase gene. Structure and regulation of expression. J Biol Chem 266:2115-2120 (Pubitemid 21909037)
15. Erion MD, Potter SC, van Poelje PD (2004) Fructose 1, 6-bisphosphatase inhibition improves oral glucose tolerance and enhances the antidiabetic action of glyburide in the ZDF rat (Abstract). Diabetologia 47(Suppl 1):0796
16. Erion MD, van Poelje PD, Dang Q, Kasibhatla SR, Potter SC, Reddy MR, Reddy KR, Jiang T, Lipscomb WN (2005) MB06322 (CS-917): A potent and selective inhibitor of fructose 1, 6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes. Proc Natl Acad Sci 102:7970-7975 (Pubitemid 40781047)
17. Erion MD, Dang Q, Reddy MR, Kasibhatla SR, Huang J, Lipscomb WN, van Poelje PD (2007) Structure-guided design of AMP mimics that inhibit fructose-1, 6-bisphosphatase with high affinity and specificity. J Am Chem Soc 129(50):15480-15490
18. Foley LH, Wang P, Dunten P, Ramsey G, Gubler ML, Wertheimer SJ (2003) Modified 3-alkyl-1, 8-dibenzylxanthines as GTP-competitive inhibitors of phosphoenolpyruvate carboxykinase. Bioorg Med Chem Lett 13:3607-3610 (Pubitemid 37141439)
19. Fonseca V, Rosenstock J, Patwardhan R, Salzman A (2000) ffect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 283(13):1695-1702 (Pubitemid 30196209)
20. Gastaldelli A, Baldi S, Pettiti M, Toschi E, Camastra S, Natali A, Landau BR, Ferrannini E (2000) Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes 49(8):1367-1373 (Pubitemid 30627434)
21. Gastaldelli A, Toschi E, Pettiti M, Frascerra S, Quiñones-Galvan A, Sironi AM, Natali A, Ferrannini E (2001) Effect of physiological hyperinsulinemia on gluconeogenesis in nondiabetic subjects and in type 2 diabetic patients. Diabetes 50:1807-1812 (Pubitemid 33641600)
22. Gerich JE, Meyer C, Woerle HJ, Stumvoll M (2001) Renal gluconeogenesis: its importance in human glucose homeostasis. Diab Care 24(2):382-391 (Pubitemid 32119142)
23. Gidh-Jain M, Zhang Y, van Poelje PD, Liang JY, Huang S, Kim J, Elliott JT, Erion MD, Pilkis SJ, Raafat el-Maghrabi M et al (1994) The allosteric site of human liver fructose-1, 6-bisphosphatase. Analysis of six AMP site mutants based on the crystal structure. J Biol Chem 269:27732-27738
24. Gitzelmann R, Steinmann B, Van Den Berghe G (1995) In: Scriver CR, Beaudet AL (eds) The metabolic and molecular basis of inherited disease, vol 1. McGraw-Hill, New York, pp 905-934
25. Henin N, Vincent MF, Van den Berghe G (1996) Stimulation of rat liver AMP-activated protein kinase by AMP analogues. Biochim Biophys Acta 1290:197-203 (Pubitemid 26184469)
26. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR, Shulman GI (2000) Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 49:2063-2069
27. Jeng CY, Sheu WH, Fuh MM, Chen YD, Reaven GM (1994) Relationship between hepatic glucose production and fasting plasma glucose concentration in patients with NIDDM. Diabetes 43:1440-1444
28. Jenssen T, Nurjhan N, Consoli A, Gerich JE (1990) Failure of substrate-induced gluconeogenesis to increase overall glucose appearance in normal humans. J Clin Invest 86:489-497
29. Ke H, Liang JY, Zhang Y, Lipscomb WN (1991) Conformational transition of fructose-1, 6-bisphosphatase: structure comparison between the AMP complex (T form) and the fructose 6-phosphate complex (R form). Biochemistry 30:4412-4420
30. Kodama H, Fujita M, Yamazaki M, Yamaguchi I (1994) The possible role of age-related increase in the plasma glucagon/insulin ratio in the enhanced hepatic gluconeogenesis and hyperglycemia in genetically diabetic (C57BL/DsJ-db/db) mice. Jpn J Pharmacol 66:281-287
31. Lamont BJ, Visinoni S, Fam BC, Kebede M, Weinrich B, Papapostolou S, Massinet H, Proietto J, Favaloro J, Andrikopoulos S (2006) Expression of human fructose-1, 6-bisphosphatase in the liver of transgenic mice results in increased glycerol gluconeogenesis. Endocrinology 147:2764-2772 (Pubitemid 43764613)
32. Landau BR, Wahren J, Chandramouli V, Schumann WC, Ekberg K, Kalhan SC (1996) Contributions of gluconeogenesis to glucose production in the fasted state. J Clin Invest 98:378-385 (Pubitemid 26255737)
33. Lee WN et al (2000) Loss of regulation of lipogenesis in the Zucker diabetic (ZDF) rat. Am J Physiol Endocrinol Metab 279:E425-E432
34. Leroith D, Taylor SI, Olefsky JM (1996) Diabetes mellitus, a fundamental and clinical text. Lippincott-Raven Publishers, Philadelphia, PA
35. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI (1998) Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 128:176-185 (Pubitemid 28078198)
36. Magnusson I, Rothman DL, Katz LD, Shulman RG, Shulman GI (1992) Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest 90:1323-1327
37. Olefsky JM (1993) Insulin resistance and the pathogenesis of non-insulin dependent diabetes mellitus: cellular and molecular mechanisms. In: Ostenson OG et al (eds) New concepts in the pathogenesis of NIDDM. Plenum Press, New York, pp 129-150
38. Parker JC, van Volkenburg MA, Levy CB, Martin WH, Burk SH, Kwon Y, Giragossian C, Gant TG, Carpino PA, McPherson RK, Vestergaard P, Treadway JL (1998) Plasma glucose levels are reduced in rats and mice treated with an inhibitor of glucose-6-phosphatase. Diabetes 47:1630-1636 (Pubitemid 28445353)
39. Pilkis SJ (1991) Hepatic gluconeogenesis/glycolysis: regulation and structure/function relationships of substrate cycle enzymes. Ann Rev Nutr 11:465-515
40. Pilkis SJ,McGraneMM, Kountz PD, el-MaghrabiMR, Pilkis J, Maryanoff BE, Reitz AB, Benkovic SJ (1986) The effect of arabinose 1, 5-bisphosphate on rat hepatic 6-phosphofructo-1-kinase and fructose-1, 6-bisphosphatase. Biochem Biophys Res Commun 138:159-166
41. Pold R, Jensen LS, Jessen N, Buhl ES, Schmitz O, Flyvbjerg A, Fujii N, Goodyear LJ, Gotfredsen CF, Brand CL, Lund S (2005) Long-term AICAR administration and exercise prevents diabetes in ZDF rats. Diabetes 54:928-934 (Pubitemid 40446305)
42. Reddy MR, Erion MD (2005) Computer-aided drug design strategies used in the discovery of fructose 1, 6-bisphosphatase inhibitors. Curr Pharm Des 11:283-294 (Pubitemid 40277858)
43. Reddy MR, Erion MD (2007) Relative binding affinities of fructose-1, 6-bisphosphatase inhibitors calculated using a quantum mechanics-based free energy perturbation method. J Am Chem Soc 129(30):9296-9297 (Pubitemid 47218793)
44. Rosini M, Mancini F, Tarozzi A, Colizzi F, Andrisano V, Bolognesi ML, Hrelia P, Melchiorre C (2006) Design, synthesis, and biological evaluation of substituted 2, 3-dihydro-1H-cyclopenta [b]quinolin-9-ylamine related compounds as fructose-1, 6-bisphosphatase inhibitors. Bioorg Med Chem 14:7846-7853 (Pubitemid 44584711)
45. 13C-NMR. Science 254:573-576
46. Skalecki K, Mularczyk W, Dzugaj A (1995) Kinetic properties of D-fructose-1, 6-bisphosphate 1-phosphohydrolase isolated from human muscle. Biochem J 310(Pt 3):1029-1035
47. Sugden MC, Holness MJ (2006) Mechanisms underlying regulation of the expression and activities of the mammalian pyruvate dehydrogenase kinases. Arch Physiol Biochem 112(3):139-149 (Pubitemid 44871041)
48. Tillmann H, Bernhard D, Eschrich K (2002) Fructose-1, 6-bisphosphatase genes in animals. Gene 291(1-2):57-66
49. Triscari J, Walker J, Feins K, Tao B, Bruce SR (2006) Multiple ascending doses of CS-917, a novel fructose 1, 6-bisphosphatase (FBPase) inhibitor, in subjects with type 2 diabetes treated for 14 days. Diabetes 55(Suppl 1):444-P
50. van Gelder J, Deferme S, Annaert P, Naesens L, De Clercq E, Van den Mooter G, Kinget R, Augustijns P (2000) Increased absorption of the antiviral ester prodrug tenofovir disoproxil in rat ileum by inhibiting its intestinal metabolism. Drug Metab Dispos 28:1394-1396
51. van Poelje PD, Potter SC, Chandramouli VC, Landau BR, Dang Q, Erion MD (2006a) Inhibition of fructose 1, 6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in ZDF rats. Diabetes 55:1747-1754 (Pubitemid 44324128)
52. van Poelje PD, Potter SC, Linemeyer DL, Erion MD (2006b) MB06322 (CS-917) lowers blood glucose in rodents by inhibiting both hepatic and renal gluconeogenesis. Diabetes 55(Suppl 1):575-P
53. van Poelje PD, Potter SC, Topczewski E, Hou J, Linemeyer DL, Erion MD (2006c) Combination therapy with pioglitazone and a fructose-1, 6-bisphosphatase inhibitor (MB06322) improves glycemic control and lactate homeostasis in male Zucker diabetic fatty (ZDF) rats. Diabetologia 49(Suppl 1):0852
54. van Schaftingen E, Hers H-G (1981) Inhibition of fructose-1, 6-bisphosphatase by fructose 2, 6-bisphosphate. Proc Natl Acad Sci USA 78:2861-2863
55. Vincent MF, Bontemps F, Van den Berghe G (1992) Inhibition of glycolysis by 5-amino-4-imidazolecarboxamide riboside in isolated rat hepatocytes. Biochem J 281:267-272
56. Vincent MF, Erion MD, Gruber HE, Van den Berghe G (1996) Hypoglycaemic effect of AIC Ariboside in mice. Diabetologia 39:1148-1155
57. Vincent MF, Marangos PJ, Gruber HE, Van den Berghe G (1991) Inhibition by AICA riboside of gluconeogenesis in isolated rat hepatocytes. Diabetes 40:1259-1266
58. Visinoni S, Fam BC, Blair A, Rantzau C, Lamont BJ, Bouwman R, Watt MJ, Proietto J, Favaloro JM, Andrikopoulos S (2008) Increased glucose production in mice overexpressing human fructose-1, 6-bisphosphatase in the liver. Am J Physiol Endocrinol Metab 295:E1132-E1141
59. von Geldern TW, Lai C, Gum RJ, Daly M, Sun C, Fry EH, Abad-Zapatero C (2006) Benzoxazole benzenesulfonamides are novel allosteric inhibitors of fructose-1, 6-bisphosphatase with a distinct binding mode. Bioorg Med Chem Lett 16:1811-1815 (Pubitemid 43267356)
60. Wajngot A, Chandramouli V, Schumann WC, Ekberg K, Jones PK, Efendic S, Landau BR (2001) Quantitative contributions of gluconeogenesis to glucose production during fasting in type 2 diabetes mellitus. Metabolism 50:47-52 (Pubitemid 32058548)
61. Walker J, Triscari J, Dmuchowski C, Kaneko T, Bruce SR (2006a) Safety and tolerability of single doses of CS-917, a novel gluconeogenesis inhibitor, in normal male volunteers. Diabetes 55(Suppl 1):2002-PO
62. Walker J, Triscari J, Dmuchowski C, Kaneko T, Bruce SR (2006b) Safety, tolerability and pharmacodynamics of multiple doses of CS-917 in normal volunteers. Diabetes 55(Suppl 1):2003-PO
63. Wright SW, Carlo AA, Carty MD, Danley DE, Hageman DL, Karam GA, Levy CB, Mansour MN, Mathiowetz AM, McClure LD, Nestor NB, McPherson RK, Pandit J, Pustilnik LR, Schulte GK, Soeller WC, Treadway JL, Wang IK, Bauer PH (2002) Anilinoquinazoline inhibitors of fructose 1, 6-bisphosphatase bind at a novel allosteric site: synthesis, in vitro characterization, and X-ray crystallography. J Med Chem 45:3865-3877
64. Wright SW, Carlo AA, Danley DE, Hageman DE, Hageman DL, Karam GA, Mansour MN, McClure LD, Pandit J, Schulte GK, Treadway JL, Wang IK, Bauer PH (2003) 3-(2-carboxyethyl)-4, 6-dichloro-1H-indole-2-carboxylic acid: an allosteric inhibitor of fructose-1, 6-bisphosphatase at the AMP site. Bioorg Med Chem Lett 13:2055-2058 (Pubitemid 36638409)
65. Wright SW, Hageman DL, McClure LD, Carlo AA, Treadway JL, Mathiowetz AM, Withka JM, Bauer PH (2001) Allosteric inhibition of fructose-1, 6-bisphosphatase by anilinoquinazolines. Bioorg Med Chem Lett 11:17-21 (Pubitemid 32006115)